

1 **Application of diagnostic network optimization in Kenya and Nepal**
2 **to design integrated, sustainable and efficient bacteriology and**
3 **antimicrobial resistance surveillance networks**

4
5 **Marie Brunetti^{1*}, Amit Singh², Sheilla Chebore³, Deepak Gyenwali⁴, Nada Malou¹, Cecilia**
6 **Ferreira¹, Tulsi Ram Gombo⁵, Jyoti Acharya⁶, Nisha Rijal⁶, Susan Githii⁷, Evelyn**
7 **Wesangula⁷, Heidi Albert⁸**

8
9 ¹ FIND, Geneva, Switzerland

10 ² FIND, Bangalore, India

11 ³ FIND, Nairobi, Kenya

12 ⁴ FIND, Kathmandu, Nepal

13 ⁵ Central Veterinary Laboratory, Kathmandu, Nepal

14 ⁶ National Public Health Laboratory, Kathmandu, Nepal

15 ⁷ National Antimicrobial Stewardship Interagency Committee, Nairobi, Kenya

16 **Corresponding author:**

17 marie.brunetti@finddx.org (MB)

18

19 **Short title (70 characters):** Designing optimized bacteriology and AMR networks in Kenya

20 and Nepal

21

22

WITHDRAWN
see manuscript DOI for details

23 **Abstract**

24 Antimicrobial resistance (AMR) is a major global public health concern, particularly in low-
25 and middle-income countries (LMICs), which experience the highest burden of AMR. Critical
26 to combatting AMR is ensuring there are effective, accessible diagnostic networks in place to
27 diagnose, monitor and prevent AMR, but many LMICs lack such networks. Consequently, there
28 is substantial need for approaches that can inform the design of efficient AMR laboratory
29 networks and sample referral systems in LMICs. Diagnostic network optimization (DNO) is a
30 geospatial network analytics approach to plan diagnostic networks and ensure greatest access to
31 and coverage of services, while maximizing the overall efficiency of the system. In this study,
32 DNO was applied to strengthen bacteriology and AMR surveillance network design in Kenya
33 and Nepal for human and animal health, by informing linkages between health facilities and
34 bacteriology testing services, and planning of sample referral routes between farms, health
35 facilities and laboratories. Data collected from the target settings in each country were entered
36 into the open-access DNO tool OptiDx, to generate baseline scenarios, which depicted the
37 current state of AMR laboratory networks and sample referral systems in the countries.
38 Subsequently, the baselines were adjusted to evaluate changing factors such as samples flows,
39 transport frequency, transport costs, and service distances. Country stakeholders then compared
40 resulting future scenarios to identify the most feasible solution for their context. The DNO
41 analyses enabled a wealth of insights that will facilitate strengthening of AMR laboratory and
42 surveillance networks in both countries. Overall, the project highlights the benefits of using a
43 data-driven approach for designing efficient diagnostic networks, to ensure better health
44 resource allocation while maximizing the impact and equity of health interventions. Given the

45 critical need to strengthen AMR laboratory and surveillance capacity, DNO should be
46 considered an integral part of diagnostic strategic planning in the future.

47 **Abstract word count: 300/300**

48

49 **Keywords:** diagnostics, laboratory network, antimicrobial resistance, bacteriology,
50 surveillance, diagnostic network optimization, sample referral system

WITHDRAWN
see manuscript DOI for details

51 **Introduction**

52 Antimicrobial resistance (AMR) is a major global public health concern and growing rates of
53 drug resistance threaten our ability to treat even common infections (1). Drug-resistant
54 infections impose huge costs on individuals and society as they spread between the
55 environment, animals and humans (1, 2). A recent landmark study on the global burden of
56 AMR found that drug-resistant bacteria directly caused 1.27 million deaths and were associated
57 with a further 4.95 million deaths in 2019 (3). It has been estimated that up to 10 million people
58 each year will die as a result of AMR by 2050 unless urgent action is taken (2).

59 The burden of AMR is particularly high in low- and middle-income countries (LMICs), as a
60 result of complex, interplaying factors. LMICs experience a high burden of infectious diseases,
61 but may lack adequate health systems, laboratory capacity, and the resources required for
62 surveillance of such diseases and diagnostic testing to inform appropriate antimicrobial use (3-
63 8). As a result, antibiotic misuse is high in LMICs, where most antibiotic prescriptions are made
64 by doctors and other medical professionals based on empirical diagnosis, without using a
65 diagnostic tool to confirm the underlying infectious agent (9, 10). Consequently, AMR is
66 further driven by the overuse of antibiotics, which encourages the spread of drug-resistant
67 bacteria. Confounding factors, such as poverty, overcrowding and improper handling of
68 contaminated waste in the environment can further contribute to AMR (8). Tackling AMR in
69 LMICs is therefore part of a wider challenge related to health and diagnostic system
70 strengthening.

71 There are numerous tests to identify infectious agents such as bacteria and fungi and test their
72 susceptibility to different antimicrobial agents. Common methods include Gram staining,

73 culture, biochemical testing and manual antimicrobial susceptibility testing (AST) (11). More
74 modern methods include testing on automated platforms such as the VITEK system, and
75 genomic sequencing (12). However, in many countries these complex devices may only be
76 available at higher tiers of the healthcare network (e.g. at a central laboratory), or may not be
77 available at all in lower-resource settings (13). This is a particular issue in severe and life-
78 threatening conditions like sepsis, where the availability of diagnostics is critical, as the risk of
79 death for the patient increases by an estimated 7.6% with every hour that passes before
80 treatment begins (14).

81 As a result, laboratory networks and sample referral systems (SRSs) between national, regional,
82 and peripheral facilities are critical for ensuring accessible and timely diagnostic testing.
83 Efficient and accessible diagnostic laboratories and SRSs at the lower levels of the health
84 system are particularly important for patient care, as healthcare practitioners require timely
85 results from the identification of pathogen and AST to effectively treat patients with the right
86 antimicrobial agent. Such networks are also vital for AMR surveillance, for example, to
87 monitor community outbreaks of multidrug-resistant bacteria and inform disease control
88 activities and treatment prescribing guidelines at a local level. AMR surveillance is typically
89 conducted using bacterial isolates sent via SRSs to higher levels of the network. However,
90 many LMICs do not have organized SRSs for bacteriology testing and AMR surveillance, and
91 patients may be referred to higher levels of the health system to access these services. When
92 they exist, SRSs often are fragmented and not integrated across diseases. In some cases, there
93 may be no access to suitable laboratories for testing.

94 Strengthening the capacity for bacteriology testing and AMR surveillance in LMICs therefore
95 requires key changes to how testing is handled at all levels of the health system and the

96 implementation of a One Health approach that recognizes the interconnection between people,
97 animals, plants, and their shared environment (15). Firstly, there is a critical need for rapid
98 diagnostic solutions in primary care, simplified blood culture methods and AST at higher levels
99 of the network, as well as digital solutions to improve result interpretation and support clinical
100 decisions. Secondly, there is a need to improve access to and optimize the use of existing tests
101 in healthcare systems for both animal and human health. In particular, there is a need for
102 systematic approaches to inform the placement and use of diagnostic instruments, human
103 resources and sample referral linkages.

104 Diagnostic network optimization (DNO) is a geospatial network analytics approach to plan
105 diagnostic networks consistent with national health goals and strategies (13, 16). DNO enables
106 analysis of the current diagnostic network and the development of evidence-based
107 recommendations around the optimal type, number and location of diagnostics and an
108 associated sample referral network that maximize access to and the overall efficiency of the
109 health system (13). DNO is being increasingly used in the public health sector to inform
110 diagnostic instrument placement, optimize sample transportation and referral mechanisms,
111 facilitate geographical prioritization and efficient integration of testing to meet the priority
112 needs of a disease programme (13, 17-21). To date, DNO has largely been used to optimize
113 diagnostic networks for patient management.

114 This study applied DNO to the design of surveillance networks in two LMICs – Kenya and
115 Nepal – looking to strengthen and optimize their diagnostic networks for AMR. Specifically,
116 DNO modelling was used to inform the optimal design of AMR laboratory and sample referral
117 networks in both countries, to improve the coverage and efficiency of AMR surveillance. Here,

118 we outline the process used to conduct the DNO analysis and key insights generated from this
119 novel application of DNO to diagnostic networks for AMR.

120

121 **Methods**

122 In this study, DNO analyses were conducted in Kenya and Nepal between July 2021 and March
123 2022 to inform the design of bacteriology and AMR surveillance networks. DNO was
124 conducted in line with established methodology (13) and according to each country's context
125 and objectives. The study aimed to optimize linkages between health facilities and bacteriology
126 testing services at different levels of the health system and assist with the planning of routes for
127 referring samples and isolates between farms, health facilities and laboratories.

128

129 **Study setting**

130 Kenya's healthcare system is structured across six tiers, starting with community and primary
131 care, up to primary, secondary and tertiary hospitals (22). Primary and secondary hospitals
132 (Levels 4 and 5) offer a wide range of services and receive high volumes of patients referred
133 from lower-level facilities. Kenya is enrolled in the World Health Organization's Global
134 Antimicrobial Resistance and Use Surveillance System (GLASS) and has five AMR
135 surveillance sites participating in the national surveillance system (23). The existing national
136 AMR surveillance strategy focuses on monitoring trends in bacterial resistance to antibiotics,
137 through a network composed of 14 AMR human health laboratories, including the National
138 Microbiology Reference Laboratory (NMRL), located in 13 counties, with plans for expansion

139 to all 47 counties (24). Testing is typically done on-site through walk-in or referred patients, as
140 bacteriology sample referrals for patient management are not in place and only a few isolate
141 referrals exist. Although Kenya has established diagnostic networks and strategic plans for the
142 management of tuberculosis (TB) and HIV (25, 26), existing SRSs for TB and HIV are
143 complex and fragmented, with varied strategies and implementation approaches across donors
144 and implementing partners.

145 In Nepal, the healthcare system is structured across four tiers, comprising community care
146 delivered by community healthcare workers, primary healthcare centres, secondary healthcare
147 facilities (e.g. district hospitals) and tertiary healthcare facilities (e.g. specialized hospitals)
148 (27). The laboratory network in Nepal is tiered, with basic diagnostic services for human health
149 available at most health facilities. Hospital-level facilities may have additional testing capacity,
150 such as instruments for detecting TB drug resistance. Nepal is also enrolled in GLASS and has
151 41 AMR surveillance sites (hospitals with an outpatient department and/or inpatient
152 department), participating in the national surveillance system (23). AMR surveillance in the
153 country started in 1999 with a limited number of participant laboratories and organisms under
154 surveillance (28). The programme has since expanded to a network of 25 human health
155 laboratories plus the National Public Health Laboratory (NPHL) in 2022, covering all seven
156 provinces of the country and seven animal health laboratories located in six provinces.
157 Surveillance networks for human and animal health in the country are separate. Through their
158 respective networks, the NPHL and the Central Veterinary Laboratory (CVL) monitor AMR
159 among the possible isolates from patients and animals, respectively, through confirmatory
160 testing and quality assurance. Currently, Nepal lacks an organized referral system for
161 bacteriology testing and AMR surveillance. As specimens are not always referred, farmers and

162 patients directly submit specimens to the nearest laboratory using their own transport system
163 and testing is done on-site. Referral of bacterial isolates for confirmatory testing at NPHL and
164 CVL is also not commonly practiced. However, Nepal has started to establish active
165 surveillance in the animal health sector to strengthen the One Health approach in AMR
166 surveillance and response (29), which this project will assist with planning and implementing.

167

168 **Objectives and expected outcomes**

169 The main objectives of the DNO analysis were to:

- 170 1. estimate projected future demand for bacteriology and AST testing and determine the
171 optimal capacity and placement of diagnostics to meet future needs in a cost-efficient
172 manner;
- 173 2. use established country diagnostic networks to model future expansion of referring
174 facilities within the network; and
- 175 3. develop optimal sample transport mechanisms for isolates referred from sentinel sites to
176 national reference laboratories to maximize surveillance coverage.

177

178 **DNO tool: OptiDx**

179 The DNO analysis was conducted using OptiDx, a web-based, open-access network analytic
180 tool, designed for use in LMICs (30). OptiDx models the impact of simultaneously changing
181 multiple parameters of network design and performance so multiple scenarios can be compared

182 and evaluated. OptiDx is currently in use across LMICs to support DNO analysis for various
183 diseases including COVID-19, HIV, TB and human papillomavirus.

184

185 **DNO process**

186 A DNO analysis typically comprises five key steps (13). An overview of the process followed
187 in Kenya and Nepal for each key step is outlined in Table 1.

188

189 **Table 1. Key components of DNO process undertaken in Kenya and Nepal**

Step	Details
Define scope	<ul style="list-style-type: none">• Define scope of analysis in Kenya and Nepal in collaboration with key stakeholders
Collate and prepare data	<ul style="list-style-type: none">• Identify data sources• Develop template for data collection• Collate and clean data
Conduct baseline analysis of diagnostic network for animal and human health to determine the existing routing, current demand,	<ul style="list-style-type: none">• Conduct baseline analysis of diagnostic networks for human health, device footprint, testing capacity and referral linkages

<p>device placement and frequency of isolate referrals</p>	<ul style="list-style-type: none"> • In Nepal, conduct baseline analysis of diagnostic networks for animal health, existing device footprint, testing capacity and referral linkages • Map available country data on testing and overlay with the existing network to understand gaps and opportunities for improved coverage and efficiency of the network, and referral integration
<p>Run customized optimization scenarios based on current testing and plans for active surveillance and compare network outputs</p>	<ul style="list-style-type: none"> • Estimate the growth in testing demand and assess scenarios to meet the projected demand using the available device footprint and potential procurement of additional devices • Project future demand for bacteriology and confirmatory testing and recommend optimal referral design, including options for integration into existing networks for other samples, transport modes, costs and resource estimates • Compare expected impact of various network designs and implementation strategies
<p>Select outputs for implementation and to support decision-making</p>	<ul style="list-style-type: none"> • Establish national datasets and dynamic network models for human and animal health that can be interrogated for future scenarios for bacteriology and antimicrobial susceptibility testing

	<ul style="list-style-type: none">• Use model outputs to inform national action plans and implementation planning• Support the development of tools/documents on outputs of the DNO exercise to inform cost and design of sample referral systems, including integrated referral systems
--	---

190

191 **1. Scope of analysis**

192 In both countries, DNO analyses were initiated in 2021, which was considered the “baseline”
193 for the AMR and bacteriology networks.

194 **Kenya**

195 In Kenya, the scope of the DNO analysis was defined in collaboration with the National
196 Antimicrobial Stewardship Interagency Committee (NASIC) and key stakeholders to ensure
197 alignment with the priority needs of the country. Kenya’s Ministry of Health requested that the
198 analysis focus on AMR networks for human health only. Stakeholders agreed that the analysis
199 would focus on including AMR within the integrated SRS, which is currently being
200 implemented in the country. As such, the DNO analysis focused on 13 counties with an AMR
201 sentinel surveillance site (shown in Fig. 1a) and covered testing for bacteriology/AMR, TB and
202 HIV. AMR sentinel surveillance sites are usually a hospital laboratory, which can collect
203 specimens, conduct testing and transport isolates to the NMRL and report surveillance data
204 based on AST conducted. Specific tests included in the analysis were: Gram stain, culture,
205 bacterial identification, AST, and quality assurance/confirmatory testing for bacteriology/AMR
206 at NMRL; GeneXpert MTB/RIF and culture/drug susceptibility testing for TB; and early infant

207 diagnosis for HIV. Previous DNO work conducted with Kenya's National TB Programme was
208 also used to inform the current project (31).

209

210 **Nepal**

211 In Nepal, discussions were initiated with government authorities and stakeholders to introduce
212 DNO and OptiDx and understand priorities for AMR surveillance. The most important need
213 identified was to strengthen and institutionalize the referral linkages between sentinel sites and
214 reference laboratories to improve AMR surveillance in human and animal health. Available
215 data on AMR testing and surveillance in Nepal were reviewed to inform the development of a
216 quantified scope of work for the DNO analysis. For animal health, it was agreed that the
217 analysis would include culture, bacterial identification, and AST on samples from poultry
218 species across the geographical scope shown in Fig 1b. For animal health, five out of the seven
219 veterinary laboratories were included, as the two remaining veterinary sentinel sites did not
220 share any data, and 331 farms and slaughterhouses were mapped to those testing sites.

221 For human health, it was agreed that the DNO analysis would cover Bagmati province with its
222 10 AMR human health sentinel sites (Fig 1c). In addition to the bacteriology/AMR programme,
223 the analysis also considered sample referrals for TB and HIV in humans. Specific tests included
224 in the analysis were: Gram stain, culture, bacterial identification, AST, bacterial re-
225 identification, confirmatory testing for bacteriology/AMR; GeneXpert MTB/RIF for TB; and
226 viral load testing for HIV.

227

228 **Fig 1.** Geographical scope of DNO analysis

229 a) in Kenya for human health

230 b) in Nepal for animal health

231 c) in Nepal for human health

232

233 2. Collation and preparation of data for analysis

234 In Kenya and Nepal, data templates were developed to collect information and key metrics to
235 help evaluate existing bacteriology sample referral and AMR surveillance networks, as of 2021.

236 Table 2 outlines the key data that were collected for Kenya and Nepal. Multiple data sources
237 were used to map the 2021 baseline network, including literature review documentation,
238 programmatic reports and laboratory datasets.

239

240 **Table 2.** Key data collected to inform DNO analyses in Kenya and Nepal

KENYA	NEPAL	
	Animal health	Human health
14 sites in 13 counties	5 sites in 4 provinces	10 sites in 1 province
<ul style="list-style-type: none">• Routes, frequency and transport modes used for TB/HIV sample referrals• Locations of microbiology laboratories and TB/HIV testing sites (geocoordinates)	<ul style="list-style-type: none">• Locations of farms (no geocoordinates, information at ward level)• Locations of veterinary laboratories (geocoordinates)	<ul style="list-style-type: none">• Routes, frequency, and transport modes used for TB/HIV samples referrals• Locations of microbiology laboratories (geocoordinates)

<ul style="list-style-type: none"> • Human resource capacity in microbiology laboratories (list and number of staff engaged in diagnostic and AST testing) • Bacteriology and AST tests performed (culture, identification, AST, etc.) • Existing testing capacity at microbiology laboratories (number of devices, tests performed on each device, etc.) • Transport costs • Test costs 	<ul style="list-style-type: none"> • Human resource capacity in veterinary laboratories (list and number of staff engaged in diagnostic and AST testing) • Bacteriology and AST tests performed (culture, identification, AST, etc.) • Existing testing capacity at veterinary laboratories (number of devices, tests performed on each device, etc.) • Transport costs • Test costs 	<ul style="list-style-type: none"> • Human resource capacity in microbiology laboratories (list and number of staff engaged in diagnostic and AST testing) • Bacteriology and AST tests performed (culture, identification, AST, etc.) • Existing testing capacity at microbiology laboratories (number of devices, tests performed on each device, etc.) • Transport costs • Test costs
---	---	---

241 AMR, antimicrobial resistance; AST, antimicrobial susceptibility testing; TB, tuberculosis.

242

243 In Nepal, there were substantial challenges with data availability and quality, notably the non-
 244 availability of the geocoordinates for health facilities and farms. Geocoordinates of the human
 245 health facilities were manually collected using Google Maps, while fictive locations of farms
 246 were created using the geographic information system QGIS. The geographic information
 247 system (GIS) file of ward distribution was imported into QGIS software to get ward surface
 248 areas and coordinates, and a number of farms were assigned to each ward using the random
 249 points inside polygon function. Farms were then placed at the centroid of the ward in urban

250 municipalities, and randomly distributed within the ward in rural municipalities. Those farm
251 locations were then converted to geocoordinates and imported into OptiDx for analysis.

252

253 **3. Building of baseline model**

254 The data collected in step 2 were entered into OptiDx to map current bacteriology diagnostic
255 and AMR surveillance networks in Kenya and Nepal (as of 2021). The baseline analyses gave a
256 geographical representation of the diagnostic networks and helped determine the existing
257 routing, current testing demand, device placement and frequency of isolate referrals for human
258 health in Kenya and for human health and animal health in Nepal. Findings from the baseline
259 assessment were presented to the respective partners in Kenya and Nepal for feedback to help
260 inform the design of future optimized scenarios and future analyses as the networks evolve.

261

262 **4. Development of customized optimization scenarios**

263 Based on the baseline analyses and feedback collected from partners, optimization scenarios
264 were created using OptiDx. In the optimized scenarios, current bacteriology and AMR networks
265 were overlaid with existing TB/HIV referral systems to identify gaps and opportunities for
266 specimen referrals and integration across diseases in both countries. Several optimized referral
267 networks were modelled, for samples and isolates referred between farms/health facilities,
268 AMR sentinel sites and national reference microbiology laboratories, and then compared based
269 on costs associated with the deployment of the different SRS designs.

270

271 **5. Selection and implementation of DNO outputs**

272 Final DNO outputs were presented to the respective Ministries of Health and stakeholders in
273 Kenya and Nepal. Outputs were evaluated to determine the most efficient sample referrals
274 through integrating needs for bacteriology/AMR SRSs with existing systems established for
275 other diseases. DNO allowed stakeholders in Kenya and Nepal to adjust inputs and constraints
276 and weigh up different elements of each scenario to identify the preferred solution for their
277 context. Based on the outputs, a practical guide was developed to support Nepal with setting up
278 and implementing a referral system for the surveillance of human AMR. In Kenya, the
279 recommended county referral systems will be used for the establishment of sample referrals
280 between selected sites and AMR laboratories, and will support the Referral System Technical
281 Working Group in negotiations with contracting courier services to provide sample referral
282 services for all specimens. The integrated sample referral system in Kenya is being
283 implemented at the county level by implementing partners and the counties. Detailed transport
284 costings were also created to support these interventions.

285 **Results**

286 Key insights from baseline and optimal network designs for AMR in Kenya and Nepal are
287 described here.

288

289 **Kenya**

290 **Baseline**

291 Between January and December 2021, a total of 100,294 bacteriology and antimicrobial
292 susceptibility tests in the 14 AMR human health laboratories were conducted in Kenya. Gram
293 stain and culture testing accounted for 71% of the total demand for bacteriology testing. Around
294 80% of the total AMR testing volume in Kenya was undertaken by just three out of the 14
295 laboratories (Moi Teaching Hospital in Uasin Gishu, Kenyatta National Hospital in Nairobi and
296 Machakos Hospital in Machakos). The overall average device utilization was low (6%) and
297 varied from 1% to 24% across sites. Across devices, CO2 incubators had the highest utilization
298 rates (17.5%). MALDI-TOF, which is present only at NMRL and one surveillance site, had low
299 utilization (1.2%), as did the automated blood culture devices that are available in most
300 surveillance sites (1.5%). Key reasons for low device utilization and demand were unserviced
301 equipment, a lack of staff training, and high facility workload.

302 Across the 13 AMR surveillance sites in the network in 2021, six of them sent isolates to the
303 NMRL for quality assurance and confirmatory testing during Q1 to Q3 2021 via the courier
304 drop-off sites (G4S, shown in orange lanes in S1 Fig). The overall volume of isolates sent at
305 baseline was low (64 isolates) but is already increasing as AMR surveillance expands and
306 isolate referrals and shipments to NMRL become a common practice across all sentinel sites.

307

308 **Future state scenarios & recommendations**

309 In Kenya, 89 Level 4 and 5 hospitals across 13 counties were identified as health facility
310 candidates to be linked with the AMR sentinel sites for sample transportation for patient
311 management. Most hospitals are already connected to the AMR sites, which are county or sub-
312 county referral hospitals, through samples referred for rapid TB or HIV molecular testing

313 conducted at AMR sites, or through samples that are pooled at AMR sites and further
314 transported to a testing site. Additionally, some AMR sites are already connected to the NMRL
315 through sample referrals for TB culture and drug susceptibility testing (depicted in S2 Fig),
316 allowing for bacteriology sample and isolate referrals to be integrated into the pre-existing
317 services supported by TB/HIV programmes and partners.

318 Fig 2 and Table 3 show a comparison of the four optimized scenarios recommended by the
319 DNO analysis for the first tier of the network (referral of patient samples from health facilities
320 to the AMR site), in terms of annual distance, transport costs and number of routes required.
321 The integration of AMR samples with the TB/HIV SRS (scenario 4) was found to optimize the
322 efficiency of the network. Annually, the integration of AMR with the existing TB/HIV SRS
323 would save an average of 210,726 km travelled and US\$ 44,481. Consequently, when possible,
324 the DNO analysis strongly recommended that referrals with pre-existing SRSs are integrated to
325 ensure sustainability and cost savings.

326

327 **Fig 2.** Annual distance, transport cost and number of routes required across optimized scenarios
328 for the first tier of network in Kenya (sample referrals from health facilities to AMR sites)

329

330

331 AMR, antimicrobial resistance; EID, early infant diagnosis of HIV; TB, tuberculosis; VL, viral load.

332

333 **Table 3.** Distance and cost savings across optimized scenarios for the first tier of network in
334 Kenya (sample referrals from health facilities to AMR sites)

335

First tier of network: Health facility to AMR site linkages	Scenario 1 No integration	Scenario 2 Partial integration with existing HIV VL & EID referrals	Scenario 3 Partial integration with existing TB GeneXpert referrals	Scenario 4 Integration with existing TB/HIV referrals
Percentage of integrated routes	0%	39%	55%	76%
Annual distance saved (km)	0	104,716	157,677	210,726
Percentage of annual distance saved	0%	30%	44%	59%
Annual transport cost saved (US\$)	0	\$22,708	\$32,810	\$44,481
Percentage of annual transport cost saved	0%	31%	44%	60%

336 AMR, antimicrobial resistance; EID, early infant diagnosis of HIV; TB, tuberculosis; VL, viral load.

337

338 An example of the recommended SRS for the first tier of the network (sample movements
 339 between the hospitals and AMR sentinel sites) is shown in Fig 3 and S1 Table. In the optimized
 340 scenario for Bungoma County, Naitiri Sub-County Hospital is linked to the nearest AMR site,
 341 which is Kitale County Referral Hospital in Trans Nzoia County. The optimized scenario
 342 creates opportunities for transport cost savings through using existing TB and HIV referrals.

343

344

345

346 **Fig 3.** Recommended bacteriology sample referral system in Bungoma County

347

348

349 Fig 4 and Table 4 show a comparison of the optimized scenarios recommended by the DNO
350 analysis for isolate transportation to NMRL in terms of annual distance, transport costs and
351 number of routes required. Findings from the analysis indicated that the optimal SRS for the
352 second tier of the network – isolate transportation to NMRL from ARM sentinel sites – would
353 be through using the current referral system for TB culture and drug susceptibility testing,
354 which is already in place for 8 AMR sites (S3 Fig). Assuming a transport frequency of twice a
355 month, this scenario (scenario 2 in Fig 4 and Table 5) would result in annual transport cost
356 savings of US\$ 8711.

357

358 **Fig 4.** Annual distance, transport cost and number of routes required across optimized scenarios
359 for the second tier of network in Kenya (AMR isolate referrals to the National Microbiology
360 Reference Laboratory)

361

362 AMR, antimicrobial resistance; C/DST, culture/drug susceptibility testing; NMRL, National Microbiology
363 Reference Laboratory; TB, tuberculosis.

364

365 **Table 4.** Distance and cost savings across optimized scenarios for the second tier of network in
366 Kenya (AMR isolate referrals to the National Microbiology Reference Laboratory)

Second tier of network: AMR site to NMRL linkages	Scenario 1 No integration	Scenario 2 Partial integration with existing TB C/DST referrals
Percentage of integrated routes	0%	62%
Annual distance saved (km)	0	39,596
Percentage of annual distance saved	0	53%
Annual transport cost saved (US\$)	0	\$8711
Percentage of annual transport cost saved	0%	53%

367 AMR, antimicrobial resistance; C/DST, culture/drug susceptibility testing; NMRL, National Microbiology

368 Reference Laboratory; TB, tuberculosis.

369

370 A costing analysis was performed to evaluate the cost of implementing the recommended SRSs,
371 using data that were provided by the county authorities and assumptions defined with NASIC
372 on a number of elements (including transport modes, distance travelled, transport frequency,
373 referral routes). When estimating the cost of moving samples from point A to B and excluding
374 other cost elements such as human resources, packaging, supplies and documentation, the
375 estimated annual transport cost was US\$ 73,987 for the first tier of the network and US\$ 16,580
376 for the second tier (S3 Table).

377

378 **Nepal: animal health**

379 **Baseline**

380 Between January and December 2021, a total of 3549 bacteriology and AST tests on faecal,
381 caecal and tissue samples from poultry species in five laboratories were conducted in Nepal;

382 42% of these were culture tests, 25% were bacterial identification tests and 33% were AST
383 tests. A large proportion of bacteriology testing for animal health in Nepal came from one site,
384 the CVL, which conducted 43% of overall bacteriology testing in the poultry population. Two
385 sites – the CVL and National Avian Disease Investigation Laboratory – were found to
386 undertake almost 70% of the overall testing volume for poultry species in Nepal. However,
387 CVL was found to receive few isolates (around 10 on an annual basis) from veterinary
388 laboratories each year for confirmatory testing due to a lack of mechanisms for referral,
389 resources, and staff training.

390 **Future state scenarios & recommendations**

391 As Nepal is embarking on active surveillance for the poultry population, the creation of a hub-
392 spoke model for animal health in Nepal was recommended for connecting farms and
393 slaughterhouses to regional veterinary laboratories to limit the distance travelled by farmers. In
394 the model, hubs (samples collection points) are located at local municipality government offices
395 to leverage the presence of veterinary technicians who could be responsible for collecting the
396 samples and transporting them to the testing laboratory. Examples of the recommended hub and
397 spoke SRS for the entire network and for Janakpur laboratory are shown in Fig 5.

398

399 **Fig 5.** Recommended sample referral system for animal health in Nepal

400 **a)** Hub-spoke model for Nepal overall

401

402 CVL, Central Veterinary Laboratory; NAL, National Avian Disease Investigation Laboratory.

403

404 **b) Hub-spoke model for Janakpur laboratory**

405

406 The recommended isolate referral system for the second tier of the network is shown in S4 Fig.

407 With only four regional veterinary laboratories in the model and a low estimated number of

408 isolates (n=72) to be sent to the CVL on an annual basis, the recommended isolate referral

409 system could ship specimens once or twice a month using a mix of motorbike and airplane as

410 modes of transportation.

411 A costing analysis was conducted to determine the estimated annual cost associated with the

412 transport of specimens across six scenarios, varying in terms of transport frequency (Table 5).

413 A network model with a maximum allowable distance of 20 km between the farm and hub was

414 also explored. In this model, 63 hubs were necessary instead of the 81 created in the network

415 model where no maximum allowable distance constraint was considered. As there are fewer

416 hubs in the network, the costs are also lower, as seen in Table 5.

417

418 **Table 5.** Estimated annual transport cost for the network from hub to regional labs and labs to

419 CVL

	Scenario 1	Scenario 2	Scenario 3	Scenario 4	Scenario 5	Scenario 6
Network linkages	Via hubs	Via hubs	Via hubs	Via hubs	Via hubs	Via hubs
Sample transport	6 times/week	6 times/week	4 times/ week	4 times/week	3 times/week	3 times/week

frequency hub-lab						
Isolate transport frequency lab-CVL	Twice/month	Monthly	Twice/month	Monthly	Twice/month	Monthly
Transport cost (US\$)	\$156,531.46	\$156,338.65	\$104,482.85	\$104,290.04	\$78,458.55	\$78,265.73
Transport cost with MAD constraint (US\$)	\$120,871.38	\$120,678.56	\$80,709.46	\$80,516.64	\$60,628.51	\$60,435.69

420 CVL, Central Veterinary Laboratory; MAD, maximum allowable distance.

421

422

423

424 **Nepal: human health**

425 **Baseline**

426 Between January and December 2021, 180,404 bacteriology and AST tests were performed in

427 10 laboratories for human health and culture tests accounted for 61% of total bacteriological

428 testing demand. For human health, just two out of 10 human health sentinel sites drove almost

429 half (48 %) of the bacteriology testing. The average utilization across devices was 29%, with

430 significant variations across laboratories (from 3% to 72%).

431 **Future state scenarios & recommendations**

432 As 15 out of the 21 AMR sentinel sites in Nepal's network for human health are already
433 sending specimens for HIV viral load testing directly to NPHL in Kathmandu, there is the
434 opportunity to leverage existing referrals and add AMR isolates to the shipment to NPHL. The
435 use of intermediate hubs located at the Provincial Public Health Laboratories was also
436 considered so that isolates could be consolidated at a more centralized location within a
437 common province and then transported together to NPHL. In these scenarios, four intermediate
438 hubs serving nine microbiology laboratories were created.

439 Fig 6 and S2 Table show a comparison of the six scenarios created for the second tier of
440 network in Nepal for human health. The hub-spoke model was estimated to be more costly than
441 the integrated transport system (US\$ 3900 versus US\$ 2600 annually) as the total annual
442 distance saved was smaller (37,762 km versus 54,298 km) and number of routes higher (16
443 versus 6). Scenario 3 and 4 with the partial integration with HIV viral load sample referrals
444 allow an annual cost saving of US\$ 1589 compared with scenario 1 (US\$ 4202).

445

446 **Fig 6.** Annual distance, transport cost and number of routes required across optimized scenarios
447 for the second tier of network in Nepal for human health (AMR isolate referrals to the National
448 Public Health Laboratory)

449

450 AMR, antimicrobial resistance; NPHL, National Public Health Laboratory; TB, tuberculosis; VL, viral
451 load.

452 The recommended direct-to-lab isolate referral system is shown in Fig 7.

453

454

455 **Fig 7. Recommended bacterial isolate referral system for human health in Nepal:**

456 **Direct to lab**

457 **a) Outside Kathmandu Valley**

458 **b) Kathmandu Valley**

WITHDRAWN
see manuscript DOI for details

459 **Discussion**

460 In this study, the application of DNO created a wealth of insights into the bacteriology and
461 AMR surveillance networks in Kenya and Nepal, and enabled the design of efficient and cost-
462 effective diagnostic networks adapted to each country's settings and priorities. Specifically, the
463 analysis highlighted key gaps and opportunities to inform the design of specimen referrals in
464 both countries. Findings from the DNO analysis also provided evidence for establishing
465 optimized sample and isolate referral networks and informed the development of an operational
466 guide for AMR isolate referrals in Nepal. Furthermore, the analyses highlighted the potential
467 for leveraging existing TB/HIV networks for bacteriology sample and isolate referrals in Kenya
468 and Nepal for human health.

469 While DNO has been successfully applied to optimize diagnostic networks for other diseases
470 like TB and HIV (18, 20, 21), this was the first large-scale application of DNO to AMR. The
471 critically high burden of AMR in LMICs carries dire consequences for the health of people and
472 animals in such settings, as drug-resistant organisms spread throughout the environment and
473 between countries. Strengthening diagnostic networks and surveillance systems is key to
474 tackling growing rates of AMR (3, 5), and as such, DNO offers lower-resource countries an
475 evidence-based, open-access approach to optimize their diagnostic networks. As scaling up
476 surveillance laboratories is a timely and costly endeavour, DNO can help design and optimize
477 specimen/isolate referral systems to increase access to testing and improve surveillance in the
478 shorter term in resource-limited settings.

479 Findings from the analyses are being used to guide decision-makers in Kenya and Nepal in
480 budgeting and action planning for the implementation of the recommended referral systems. In

481 Kenya, the national SRS technical working group is currently engaging an external provider to
482 provide sample referral services for all specimens, and the DNO outputs will be used to support
483 the design and implementation of the integrated model. In Nepal, the recommended referral
484 network design, proposed route maps and operational guidance will be used to establish a
485 strong and sustained isolate referral network for human health and animal health.

486 The DNO analyses in Kenya and Nepal also provided a number of learnings and considerations
487 that can be used to guide future applications of DNO to AMR. Firstly, when working on AMR
488 laboratory networks, it is important to consider that AMR programmes are often relatively new
489 in LMICs compared with other more established national disease programmes like TB and
490 HIV. In this study, DNO was a new concept to the national AMR programmes, which meant
491 the benefits of the approach and specific outputs that countries could use had to be
492 communicated clearly to stakeholders who were unfamiliar with the process.

493 Early engagement with the country stakeholders was therefore important to align partners on
494 the objectives of and benefits from DNO upfront, and drive engagement with the project. Work
495 was undertaken to highlight the benefits of DNO for the AMR programmes and define scopes
496 for the analyses that took the local context and national priorities into account, to make sure
497 outputs were impactful and useful. Early engagement was also important to identify and address
498 any capacity building needs that stakeholders may have had around conducting a DNO analysis.
499 Building the capacity of the national AMR programmes and key stakeholders around DNO is
500 important to enable an inclusive and country-owned process and ensure that implementable
501 outputs are prioritized during the process. For settings where geospatial analysis is a new
502 concept, an initial laboratory mapping exercise may also be beneficial to secure interest in DNO

503 and give stakeholders the skills to evaluate network designs and refine questions to be
504 addressed by the full DNO analysis.

505 This study also highlights that newer programmes like AMR should utilize data-driven strategic
506 planning to design diagnostic networks as early as possible, to reduce network inefficiencies,
507 avoidable costs, and challenges with access and coverage from the start. Utilizing DNO enables
508 the deployment of diagnostic networks based on need for services rather than geographic or
509 administrative considerations.

510 Another key consideration when conducting any DNO analysis is that the availability and
511 quality of data significantly affect the resources needed and timelines for conducting a DNO, as
512 well as outcomes of the analysis. Therefore, before undertaking any analysis, it is essential to
513 ascertain that key data inputs, such as geocoordinates of health facilities and testing sites, are
514 available. In terms of AMR specifically, the nature of bacteriology and AMR networks may
515 also present some challenges compared with other disease-specific diagnostic networks such as
516 TB/HIV. In particular, defining tests, testing capacity, device-test combinations and estimating
517 test costs can be challenging, as bacteriology testing comprises a sequence of different steps
518 than cannot be separated from each other. In addition, an important component of bacteriology
519 and AST testing is manual testing (e.g. culture), which is more difficult to model than machine-
520 based testing. Furthermore, as DNO is most effective when embedded in planning/funding
521 cycles, a DNO analysis needs to be conducted at an appropriate time, when insights from the
522 analysis can contribute to the development of evidence-based national strategic plans, funding
523 requests, resource allocation, or procurement and operational planning.

524 Finally, it is important to note that the value and impact of a DNO analysis will ultimately
525 depend on whether the suggested interventions are adopted and how well they are implemented

526 and monitored. Consequently, plans should be in place to support the practical implementation
527 of interventions and for the monitoring and evaluation of interventions once established.

528 Application of DNO to AMR also presents opportunities to address other potential questions
529 and topics that may be of interest in the future, including sequencing capacity placement, how
530 best to support AMR surveillance efforts, and where diagnostic network capacity for
531 bacteriology and AST could be integrated with testing for other diseases to increase access and
532 efficiency.

533 Limitations of this study largely related to the availability of data for the DNO. In Nepal, the
534 analysis was limited in geographic scope as much of the data need for a countrywide analysis
535 (e.g. geocoordinates, laboratory data) were not available. Some of the approaches utilized to
536 overcome data issues included using approximate farm locations, estimating annual data for
537 2021 using quarterly/biannual data, and modelling testing capacity. These factors could have
538 affected the precision of the recommended network designs in Nepal, but provided stakeholders
539 with an initial analysis that would have not been available otherwise.

540 Overall, the project highlights the benefits of using a data-driven approach for designing
541 efficient diagnostic networks, to ensure better health resource allocation while maximizing the
542 impact and equity of health interventions. Given the critical need to strengthen AMR laboratory
543 and surveillance capacity, network mapping and optimization should be considered an integral
544 part of diagnostic strategic planning in the future.

545 **Acknowledgements**

546 The authors would like to thank André Trollip, FIND, for his technical support on the AMR
547 laboratory testing and costing, Kinuthia Bubi, FIND, for support with project coordination and
548 administrative support, and Dr Runa Jha and Lilee Shrestha from NPHL Nepal for their support
549 to carry out this study. Medical writing support was provided by Talya Underwood, MPhil, of
550 Anthos Communications Ltd, UK, funded by FIND, according to Good Publication Practice
551 guidelines.

552

553 **Data sharing statement**

554 The minimal dataset has been uploaded in the Supporting Information files. Data requests should
555 be directed to Dr Tulsi Gompo, Central Veterinary Laboratory, Nepal, (contact via
556 tulsigompo@gmail.com), to Jyoti Acharya, National Public Health Laboratory, Nepal, (contact
557 via jyotigan30@gmail.com), to Dr Evelyn Wesangula, National Antimicrobial Stewardship
558 Interagency Committee, Kenya (contact via wesangulaeva@gmail.com). All other underlying
559 data are provided in the manuscript and/or the Supporting Information files.

560

561 **Funding**

562 This work was funded by the Department of Health and Social Care's Fleming Fund using UK
563 aid. The views expressed in this publication are those of the authors and not necessarily those of
564 the UK Department of Health and Social Care or its Management Agent, Mott MacDonald.

565

566 **Contributors**

567 Conceptualization: Heidi Albert, Cecilia Ferreyra, Nada Malou

568 Data curation: Marie Brunetti, Amit Singh

569 Formal analysis: Marie Brunetti, Amit Singh, Sheilla Chebore

570 Funding acquisition: Heidi Albert, Cecilia Ferreyra

571 Investigation: Marie Brunetti, Sheilla Chebore, Deepak Gyenwali, Nisha Rijal, Amit Singh

572 Methodology: Heidi Albert, Marie Brunetti, Amit Singh

573 Project administration : Heidi Albert, Marie Brunetti, Cecilia Ferreyra, Deepak Gyenwali, Nada

574 Malou

575 Supervision: Heidi Albert, Jyoti Acharya, Cecilia Ferreyra, Susan Githii, Tulsi Gombo, Nada

576 Malou, Evelyn Wesangula

577 Validation: Heidi Albert, Marie Brunetti, Jyoti Acharya, Susan Githii, Sheilla Chebore, Tulsi

578 Gombo, Amit Singh, Evelyn Wesangula

579 Visualization: Heidi Albert, Marie Brunetti, Amit Singh

580 Writing – original draft: Heidi Albert, Marie Brunetti

581 Writing – review & editing: Heidi Albert, Jyoti Acharya, Marie Brunetti, Sheilla Chebore, Cecilia

582 Ferreyra, Susan Githii, Tulsi Gombo, Deepak Gyenwali, Nada Malou, Nisha Rijal, Amit Singh,

583 Evelyn Wesangula

584

585 **Declaration of interests**

586 Heidi Albert, Marie Brunetti, Cecilia Ferreyra, Deepak Gyenwali and Amit Singh are employed
587 by FIND, the global alliance for diagnostics. Sheilla Chebore and Nada Malou were consultants
588 for FIND during the project. FIND is a not-for-profit foundation that supports the evaluation of
589 publicly prioritized tuberculosis assays and the implementation of WHO-approved (guidance and
590 prequalification) assays using donor grants. FIND has product evaluation agreements with
591 several private sector companies that design diagnostics for tuberculosis and other diseases.
592 These agreements strictly define FIND's independence and neutrality with regard to these private
593 sector companies.

594

595

596 **References**

597

- 598 1. World Health Organization. Antimicrobial resistance 2021 [Available from:
599 <https://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance>.
- 600 2. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations:
601 Government of the United Kingdom; 2016.
- 602 3. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial
603 resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629-55.
- 604 4. Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al.
605 Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered
606 picture. *Antimicrobial Resistance & Infection Control*. 2021;10(1):63.
- 607 5. Sulis G, Sayood S, Gandra S. Antimicrobial resistance in low- and middle-income
608 countries: current status and future directions. *Expert Rev Anti Infect Ther*. 2022;20(2):147-60.
- 609 6. Yadav H, Shah D, Sayed S, Horton S, Schroeder LF. Availability of essential
610 diagnostics in ten low-income and middle-income countries: results from national health
611 facility surveys. *The Lancet Global Health*. 2021;9(11):e1553-e60.
- 612 7. Leslie HH, Spiegelman D, Zhou X, Kruk ME. Service readiness of health facilities in
613 Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United
614 Republic of Tanzania. *Bull World Health Organ*. 2017;95(11):738-48.

- 615 8. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of
616 Antibiotic Resistance Transmission in Low- and Middle-Income Countries from a "One Health"
617 Perspective-A Review. *Antibiotics* (Basel). 2020;9(7).
- 618 9. Sulis G, Adam P, Nafade V, Gore G, Daniels B, Daftary A, et al. Antibiotic prescription
619 practices in primary care in low- and middle-income countries: A systematic review and meta-
620 analysis. *PLoS Med*. 2020;17(6):e1003139.
- 621 10. Do NTT, Vu HTL, Nguyen CTK, Punpuing S, Khan WA, Gyapong M, et al.
622 Community-based antibiotic access and use in six low-income and middle-income countries: a
623 mixed-method approach. *The Lancet Global Health*. 2021;9(5):e610-e9.
- 624 11. Giuliano C, Patel CR, Kale-Pradhan PB. A Guide to Bacterial Culture Identification
625 And Results Interpretation. Pt. 2019;44(4):192-200.
- 626 12. van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, et al.
627 Developmental roadmap for antimicrobial susceptibility testing systems. *Nature Reviews*
628 *Microbiology*. 2019;17(1):51-62.
- 629 13. FIND. Diagnostic network optimization: A network analytics approach to design
630 patient-centred and cost-efficient diagnostic systems 2021 [Available from:
631 [https://www.finddx.org/wp-content/uploads/2021/11/Guide-to-Diagnostic-Network-](https://www.finddx.org/wp-content/uploads/2021/11/Guide-to-Diagnostic-Network-Optimization_15.11.2021.pdf)
632 [Optimization_15.11.2021.pdf](https://www.finddx.org/wp-content/uploads/2021/11/Guide-to-Diagnostic-Network-Optimization_15.11.2021.pdf).
- 633 14. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of
634 hypotension before initiation of effective antimicrobial therapy is the critical determinant of
635 survival in human septic shock. *Crit Care Med*. 2006;34(6):1589-96.

- 636 15. World Health Organization. One Health 2017 [Available from:
637 <https://www.who.int/news-room/questions-and-answers/item/one-health>.
- 638 16. Nichols K, Girdwood SJ, Inglis A, Ondoa P, Sy KTL, Benade M, et al. Bringing Data
639 Analytics to the Design of Optimized Diagnostic Networks in Low- and Middle-Income
640 Countries: Process, Terms and Definitions. *Diagnostics (Basel)*. 2020;11(1).
- 641 17. Albert H, Purcell R, Wang YY, Kao K, Mareka M, Katz Z, et al. Designing an
642 optimized diagnostic network to improve access to TB diagnosis and treatment in Lesotho.
643 *PLOS ONE*. 2020;15(6):e0233620.
- 644 18. Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S.
645 Optimizing viral load testing access for the last mile: Geospatial cost model for point of care
646 instrument placement. *PLOS ONE*. 2019;14(8):e0221586.
- 647 19. Kiyaga C, Sendagire H, Joseph E, McConnell I, Grosz J, Narayan V, et al. Uganda's
648 New National Laboratory Sample Transport System: A Successful Model for Improving Access
649 to Diagnostic Services for Early Infant HIV Diagnosis and Other Programs. *PLOS ONE*.
650 2013;8(11):e78609.
- 651 20. Nichols BE, Girdwood SJ, Crompton T, Stewart-Isherwood L, Berrie L, Chimhamhiwa
652 D, et al. Impact of a borderless sample transport network for scaling up viral load monitoring:
653 results of a geospatial optimization model for Zambia. *J Int AIDS Soc*. 2018;21(12):e25206.
- 654 21. Robin TA, Khan MA, Kabir N, Rahaman ST, Karim A, Mannan, II, et al. Using spatial
655 analysis and GIS to improve planning and resource allocation in a rural district of Bangladesh.
656 *BMJ Glob Health*. 2019;4(Suppl 5):e000832.
- 657 22. Republic of Kenya Ministry of Health. Kenya Health Policy 2014–2030. 2014.

- 658 23. World Health Organization. Global Antimicrobial Resistance and Use Surveillance
659 System (GLASS) Report: 2021. 2021.
- 660 24. Government of Kenya. National Action Plan for the Prevention and Containment of
661 Antimicrobial Resistance. 2017.
- 662 25. Republic of Kenya Ministry of Health. Kenya AIDS Strategic Framework II.
- 663 26. Republic of Kenya Ministry of Health. National Strategic Plan for Tuberculosis,
664 Leprosy and Lung Health. 2019.
- 665 27. Adhikari B, Mishra SR, Schwarz R. Transforming Nepal's primary health care delivery
666 system in global health era: addressing historical and current implementation challenges.
667 Globalization and Health. 2022;18(1):8.
- 668 28. Acharya KP, Wilson RT. Antimicrobial Resistance in Nepal. Front Med (Lausanne).
669 2019;6:105.
- 670 29. The Fleming Fund. A Protocol for Active AMR Surveillance in Poultry. 2019.
- 671 30. OptiDx. OptiDx [Available from: <https://www.optidx.org/>].
- 672 31. FIND. Optimizing TB diagnostic networks to improve patient access to quality TB
673 diagnosis and treatment 2018 [Available from: [https://nltp.co.ke/wp-](https://nltp.co.ke/wp-content/uploads/2020/11/DXNetwork-Optimisation_FIND_Kenya_FINAL_01DEC18.pdf)
674 [content/uploads/2020/11/DXNetwork-Optimisation_FIND_Kenya_FINAL_01DEC18.pdf](https://nltp.co.ke/wp-content/uploads/2020/11/DXNetwork-Optimisation_FIND_Kenya_FINAL_01DEC18.pdf)].
- 675
- 676
- 677
- 678

679 **Supporting information**

680 **S1 Table.** Recommended bacteriology sample referral system for hospitals in Bungoma County

681 **S2 Table.** Distance and cost savings across optimized scenarios for the second tier of network
682 in Nepal for human health (AMR isolate referrals to the National Public Health Laboratory)

683 AMR, antimicrobial resistance; NPHL, National Public Health Laboratory; TB, tuberculosis; VL,
684 viral load.


685 **S3 Table.** Distance and cost savings across optimized scenarios for the second tier of network
686 in Kenya (AMR isolate referrals to the National Microbiology Reference Laboratory)

687 **S1 Fig.** Isolate referrals at baseline in Kenya

688 **S2 Fig.** Baseline sample referral network for human health in Kenya

689 **S3 Fig.** Optimized isolate referral system in Kenya recommended by model


690 **S4 Fig.** Recommended animal health sample referral system for isolates in Nepal



Figure




Figure




Figure


Health facility to AMR site linkages



Figure




Figure




Figure


AMR site to NMRL linkages



Figure




Figure




Figure


AMR sentinel site to NPHL linkages



Figure



Figure



Figure